Compare RNA & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNA | NREF |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.6M | 244.2M |
| IPO Year | 2025 | N/A |
| Metric | RNA | NREF |
|---|---|---|
| Price | $13.08 | $13.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 2 |
| Target Price | ★ $69.26 | $14.50 |
| AVG Volume (30 Days) | ★ 2.1M | 47.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | $24.65 |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | $4.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $12.14 |
| 52 Week High | $73.06 | $16.80 |
| Indicator | RNA | NREF |
|---|---|---|
| Relative Strength Index (RSI) | 5.61 | 31.12 |
| Support Level | $13.06 | $12.36 |
| Resistance Level | $72.52 | $15.25 |
| Average True Range (ATR) | 1.05 | 0.43 |
| MACD | -0.24 | -0.17 |
| Stochastic Oscillator | 3.62 | 7.21 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.